TABLE 2.
Alterations in gyrA and parC genes of 87 N. gonorrhoeae strains
| Patterna | Resistance phenotype | Amino acid substitution in:
|
Ciprofloxacin MIC (mg/liter) | No. (%) of strains | ||||
|---|---|---|---|---|---|---|---|---|
| GyrA
|
ParC
|
|||||||
| Ser-91 (TCC) | Asp-95 (GAC) | Asp-86 (GAC) | Ser-87 (AGT) | Glu-91 (GAG) | ||||
| M1 | Cips | 0.0075 | 9 | |||||
| M2 | Cipi | Phe (TTC) | Gly (GGC) | 0.125 | 2 (2.56) | |||
| M3 | Cipi | Phe (TTC) | Ala (GCC) | Asn (AAC) | 0.125-0.25 | 6 (7.69) | ||
| M4 | Cipi | Phe (TTC) | Ala (GCC) | 0.125-0.25 | 10 (12.82) | |||
| M5 | Cipi | Phe (TTC) | Gly (GGC) | Gln (CAG) | 0.5 | 2 (2.56) | ||
| M6 | Cipi | Phe (TTC) | Asn (AAC) | Gly (GGG) | 1 | 1 (1.28) | ||
| M7 | Cipr | Phe (TTC) | Asn (AAC) | Lys (AAG) | 1 | 1 (1.28) | ||
| M8 | Cipr | Phe (TTC) | Asn (AAC) | 1 | 2 (2.56) | |||
| M9 | Cipr | Phe (TTC) | Ala (GCC) | Asn (AAT) | 1-2 | 4 (5.12) | ||
| M10 | Cipr | Phe (TTC) | Ala (GCC) | Ala (GCG) | 2 | 3 (3.84) | ||
| M11 | Cipr | Phe (TTC) | Ala (GCC) | Gly (GGG) | 2 | 1 (1.28) | ||
| M12 | Ciph | Phe (TTC) | Asn (AAC) | Arg (AGG) | 4 | 1 (1.28) | ||
| M13 | Ciph | Phe (TTC) | Gly (GGC) | Arg (CGT) | 4-8 | 16 (20.51) | ||
| M14 | Ciph | Phe (TTC) | Asn (AAC) | Arg (CGT) | 4-8 | 9 (11.54) | ||
| M15 | Ciph | Phe (TTC) | Ala (GCC) | Asn (AAC) | Ilc (ATT) | 16 | 2 (2.56) | |
| M16 | Ciph | Phe (TTC) | Ala (GCC) | Arg (CGT) | Ala (GCG) | 4-16 | 18 (23.07) | |
a
The biochip assay identified 15 different alteration patterns involved in the formation of ciprofloxacin resistance. M1, wild type; M2 to M16, mutation types.